Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 16/20 | 0.69 |
| ▸ | CRBN | Q96SW2 | 16/20 | 0.69 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30706226 | 0.93 | DDB1 (0.75) | DDB1CRBNGPR119 | |
| SCHEMBL30768785 | 0.93 | DDB1 (0.75) | DDB1CRBNGPR119 | |
| SCHEMBL30776681 | 0.93 | DDB1 (0.75) | DDB1CRBNGPR119 | |
| SCHEMBL25586739 | 0.93 | DDB1 (0.75) | DDB1CRBNGPR119 | |
| SCHEMBL30706095 | 0.92 | CRBN (0.61) | DDB1CRBNGPR119 | |
| SCHEMBL26927476 | 0.92 | CRBN (0.61) | DDB1CRBNGPR119 | |
| SCHEMBL31513034 | 0.91 | DDB1 (0.60) | DDB1CRBNGPR119 | |
| SCHEMBL31513004 | 0.91 | DDB1 (0.60) | DDB1CRBNGPR119 | |
| SCHEMBL30731868 | 0.91 | DDB1 (0.60) | DDB1CRBNGPR119 | |
| SCHEMBL26925754 | 0.91 | DDB1 (0.60) | DDB1CRBNGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4581025-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Auron Therapeutics, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024220843-A1 | TECHNOLOGIES TARGETING CELL STATES | AURON THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024050078-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AURON THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | WO | disclosed |